Get the Stockscreener App
937.44
1.26%
11.63
After Hours:
935.00
-2.44
-0.26%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $937.44, with a volume of 6.41M.
It is up +1.26% in the last 24 hours and up +10.93% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$925.81
Open:
$928
24h Volume:
6.41M
Relative Volume:
1.39
Market Cap:
$887.25B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
46.36
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
+11.01%
1M Performance:
+10.93%
6M Performance:
+20.94%
1Y Performance:
+20.74%
1-Day Range:
$916.26
$949.90
1-Week Range:
$834.19
$955.46
52-Week Range:
$623.78
$955.46
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
937.44 | 828.62B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.97 | 448.13B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
219.04 | 383.12B | 59.64B | 2.36B | 18.24B | 1.3253 |
|
NVS
Novartis Ag Adr
|
126.57 | 240.81B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
85.78 | 209.46B | 63.99B | 19.05B | 14.72B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly CEO talks deal to cut medication prices with the Trump administration - NBC News
Trump Announces Deals With Lilly, Novo to Cut Weight Loss Drug Prices - AJMC
Denali Therapeutics is losing Carole Ho, as she heads to Lilly as head of neuroscience - The Business Journals
Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth - Investing News Network
Novo Nordisk, Lilly strike deal with Trump to slash weight-loss drug prices - Reuters
Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts - Benzinga
Eli Lilly expects US FDA approval for oral obesity drug in March 2026 - Reuters
Lilly, Novo to Lower Obesity Drug Prices in Trump Deal - Bloomberg.com
Eli Lilly adds two executives to leadership team amid pipeline push - Investing.com Canada
Denali says chief medical officer Carole Ho to depart to join Eli Lilly - TipRanks
Denali Therapeutics Announces Board and Executive Leadership Updates - GlobeNewswire Inc.
Watch Lilly, Novo to Lower Obesity Drug Prices with Trump Deal - Bloomberg.com
Weight-loss drug makers announce pricing agreement with Trump - Al Jazeera
Lilly cuts weight loss drug costs in White House deal - Fox 59
White House partners with Lilly, Novo Nordisk for TrumpRx - Mobi Health News
FDA reveals 2nd round of 'national priority' voucher winners, including obesity giants Lilly and Novo - Fierce Biotech
Eli Lilly (LLY) to Cut Prices on GLP-1 Weight Loss Drugs - GuruFocus
Lilly’s Amylin Agonist Headed to Phase III After Eliciting up to 20% Weight Loss - BioSpace
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans - Investing News Network
Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk - CNBC
Eli Lilly (LLY) Expands Access to Obesity Medications, Reduces C - GuruFocus
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx - Benzinga
Mark Cuban applauds longtime foe Donald Trump for slashing Ozempic cost: 'I think it's great' - Business Insider
Eli Lilly (NYSE: LLY) sets $50/month Medicare cap for Zepbound and orforglipron, if approved - Stock Titan
White House Strikes GLP-1 Pricing Deal With Lilly, Novo - BioSpace
Trump announces deal to sell some weight loss drugs for as low as $150 on TrumpRX - WJLA
Eli Lilly, Novo Nordisk to Cut Obesity Drug Prices Under Deals With Trump Administration - MarketScreener
Eli Lilly’s Stock (LLY) Falls After Trump Announces Deal to Lower Weight-Loss Drug Prices - TipRanks
Eli Lilly, Novo win tariff reprieve as part of drug pricing deal - Seeking Alpha
US, Lilly, Novo to Announce Deal to Cut GLP-1 Prices (Trump's Remarks) - Bloomberg.com
Eli Lilly, Novo to cut GLP-1 cost; airline stocks fall on FAA cut - Yahoo Finance
Trump secures Medicare deals with Lilly, Novo to cut GLP-1 prices - Modern Healthcare
Watch Lilly, Novo Cut Deal to Lower Drug Prices in Exchange for Tariff Relief - Bloomberg.com
Trump announces big price cuts for weight-loss drugs in Lilly and Novo deal - Capital Brief
Trump administration announces deal for GLP-1s under Most Favored Nation policy - WTNH.com
Eli Lilly, Novo Nordisk to lower Obesity Drug cost, strike pricing deal with Trump — 'Triumph for American patients' - livemint.com
Wolfe Adjusts Price Target on Eli Lilly and Company to $1,050 From $925 - MarketScreener
Eli Lilly (LLY) Agrees to Lower Obesity Drug Prices Under New De - GuruFocus
Eli Lilly, Novo Nordisk strike deals with White House to cut prices of weight loss drugs - Fierce Pharma
Eli Lilly, Novo rise after striking drug pricing deal with Trump administration - TradingView
Trump Announces Deals With Eli Lilly, Novo Nordisk To Lower Obesity Drug Prices - Stocktwits
Trump unveils deal with Lilly, Novo to expand coverage, lower costs on obesity drugs - Indianapolis Business Journal
Trump announces deal with Lilly, Novo to expand access to weight loss drugs, cut prices - statnews.com
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage - CNBC
Updated: Trump lands sweeping cost cuts on Lilly, Novo weight loss drugs in exchange for Medicare coverage - Endpoints News
Lilly moves obesity drug to late-stage trials after it shows promise - Reuters
Eli Lilly (LLY) and Novo Nordisk (NVO) Set for Major Drug-Pricin - GuruFocus
Eli Lilly's next generation weight loss drug shows promise, early trial results suggest - abcnews.go.com
Following positive results: Eli Lilly sends obesity candidate into phase III - medwatch.com
Eli Lilly links amylin agonist to 20% weight loss, sparking charge into phase 3 - Fierce Biotech
Eli Lilly’s Eloralintide Matches Zepbound’s Weight Loss in Mid-Stage Obesity Trial - Bloomberg.com
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):